Cerevel is a Massachusetts-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of neuroscience diseases.
AbbVie Acquires Cerevel Therapeutics for Neuroscience
AbbVie acquired Cerevel Therapeutics for $8.7 billion to expand its neurology portfolio, integrating innovative CNS therapies including Tavapadon for Parkinson's disease and Emraclidine for schizophrenia.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.